These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 33199881)

  • 21. Safety and efficacy of esaxerenone in Japanese hypertensive patients with heart failure with reduced ejection fraction: A retrospective study.
    Iwahana T; Saito Y; Okada S; Kato H; Ono R; Kobayashi Y
    PLoS One; 2021; 16(11):e0259485. PubMed ID: 34748605
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Pharmacological profile, clinical efficacy, and safety of esaxerenone (Minnebro
    Yamakawa S; Homma T; Yamada M; Igawa Y; Yoshimura M
    Nihon Yakurigaku Zasshi; 2020; 155(5):340-350. PubMed ID: 32879177
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Management of hyperkalemia during treatment with mineralocorticoid receptor blockers: findings from esaxerenone.
    Rakugi H; Yamakawa S; Sugimoto K
    Hypertens Res; 2021 Apr; 44(4):371-385. PubMed ID: 33214722
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and Safety of Esaxerenone in Hypertensive Patients with Diabetes Mellitus Undergoing Treatment with Sodium-Glucose Cotransporter 2 Inhibitors (EAGLE-DH).
    Motoki H; Inobe Y; Fukui T; Iwasaki A; Hiramitsu S; Koyama S; Masuda I; Sekimura N; Yamamoto K; Sato A; Komatsu M; Taguchi T; Shiosakai K; Sugimoto K; Kuwahara K
    Adv Ther; 2023 Nov; 40(11):5055-5075. PubMed ID: 37733211
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of esaxerenone (CS-3150) in primary hypertension: a meta-analysis.
    Sun R; Li Y; Lv L; Zhang W; Guo X
    J Hum Hypertens; 2024 Feb; 38(2):102-109. PubMed ID: 38177694
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Single- and multiple-dose escalation study to assess pharmacokinetics, pharmacodynamics and safety of oral esaxerenone in healthy Japanese subjects.
    Kato M; Furuie H; Shimizu T; Miyazaki A; Kobayashi F; Ishizuka H
    Br J Clin Pharmacol; 2018 Aug; 84(8):1821-1829. PubMed ID: 29688582
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nighttime home blood pressure lowering effect of esaxerenone in patients with uncontrolled nocturnal hypertension: the EARLY-NH study.
    Kario K; Nishizawa M; Kato M; Ishii H; Uchiyama K; Nagai M; Takahashi N; Asakura T; Shiraiwa T; Yoshida T; Kaneshiro M; Taguchi T; Shiosakai K; Sugimoto K
    Hypertens Res; 2023 Jul; 46(7):1782-1794. PubMed ID: 37173430
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Recent progress in the diagnosis and treatment of primary aldosteronism.
    Yoshida Y; Shibata H
    Hypertens Res; 2023 Jul; 46(7):1738-1744. PubMed ID: 37198444
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The renoprotective effect of esaxerenone independent of blood pressure lowering: a post hoc mediation analysis of the ESAX-DN trial.
    Okuda Y; Ito S; Kashihara N; Shikata K; Nangaku M; Wada T; Sawanobori T; Taguri M
    Hypertens Res; 2023 Feb; 46(2):437-444. PubMed ID: 36100672
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Primary aldosteronism in hypertensive patients: clinical implications and target therapy.
    Papanastasiou L; Markou A; Pappa T; Gouli A; Tsounas P; Fountoulakis S; Kounadi T; Tsiama V; Dasou A; Gryparis A; Samara C; Zografos G; Kaltsas G; Chrousos G; Piaditis G
    Eur J Clin Invest; 2014 Aug; 44(8):697-706. PubMed ID: 24909545
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical Pharmacokinetics and Pharmacodynamics of Esaxerenone, a Novel Mineralocorticoid Receptor Antagonist: A Review.
    Janković SM; Janković SV
    Eur J Drug Metab Pharmacokinet; 2022 May; 47(3):291-308. PubMed ID: 35190999
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Esaxerenone: First Global Approval.
    Duggan S
    Drugs; 2019 Mar; 79(4):477-481. PubMed ID: 30806972
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Crystal structure of the mineralocorticoid receptor ligand-binding domain in complex with a potent and selective nonsteroidal blocker, esaxerenone (CS-3150).
    Takahashi M; Ubukata O; Homma T; Asoh Y; Honzumi M; Hayashi N; Saito K; Tsuruoka H; Aoki K; Hanzawa H
    FEBS Lett; 2020 May; 594(10):1615-1623. PubMed ID: 31991486
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rationale and design of a multicenter randomized study comparing the efficacy and safety of esaxerenone versus trichlormethiazide in patients with uncontrolled essential hypertension: EXCITE-HT study.
    Kario K; Ohishi M; Katsuya T; Taguchi T; Tanabe A; Sugimoto K; Shimosawa T
    J Clin Hypertens (Greenwich); 2023 Sep; 25(9):861-867. PubMed ID: 37551054
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Esaxerenone (CS-3150) in Patients with Type 2 Diabetes and Microalbuminuria (ESAX-DN): Phase 3 Randomized Controlled Clinical Trial.
    Ito S; Kashihara N; Shikata K; Nangaku M; Wada T; Okuda Y; Sawanobori T
    Clin J Am Soc Nephrol; 2020 Dec; 15(12):1715-1727. PubMed ID: 33239409
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Esaxerenone: blood pressure reduction and cardiorenal protection without reflex sympathetic activation in salt-loaded stroke-prone spontaneously hypertensive rats.
    Ikeda S; Shinohara K; Kashihara S; Matsumoto S; Yoshida D; Nakashima R; Ono Y; Matsushima S; Tsutsui H; Kinugawa S
    Hypertens Res; 2024 Aug; 47(8):2133-2143. PubMed ID: 38802501
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Randomized, Double-Blind, Single-Dose, Placebo-Controlled Crossover Study to Evaluate the Effects of Esaxerenone on QTc Interval in Healthy Subjects.
    Mendell J; Kobayashi F; Shimizu T
    Clin Pharmacol Drug Dev; 2020 Aug; 9(6):709-718. PubMed ID: 32255542
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cardioprotective Effects of a Nonsteroidal Mineralocorticoid Receptor Blocker, Esaxerenone, in Dahl Salt-Sensitive Hypertensive Rats.
    Rahman A; Sawano T; Sen A; Hossain A; Jahan N; Kobara H; Masaki T; Kosaka S; Kitada K; Nakano D; Imamura T; Ohsaki H; Nishiyama A
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33669786
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of a novel nonsteroidal selective mineralocorticoid receptor antagonist, esaxerenone (CS-3150), on blood pressure and renal injury in high salt-treated type 2 diabetic mice.
    Bhuiyan AS; Rafiq K; Kobara H; Masaki T; Nakano D; Nishiyama A
    Hypertens Res; 2019 Jun; 42(6):892-902. PubMed ID: 30664703
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Home blood pressure-lowering effect of esaxerenone versus trichlormethiazide for uncontrolled hypertension: a predefined subanalysis of the EXCITE-HT randomized controlled trial by basal calcium channel blocker versus angiotensin receptor blocker.
    Kario K; Ohbayashi H; Hashimoto M; Itabashi N; Kato M; Uchiyama K; Hirano K; Nakamura N; Miyamoto T; Nagashima H; Ishida H; Ebe Y; Hatta T; Fukui T; Shimosawa T; Katsuya T; Taguchi T; Tanabe A; Ohishi M;
    Hypertens Res; 2024 Oct; ():. PubMed ID: 39394512
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.